Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas

被引:130
作者
Sholl, Lynette M. [1 ]
Weremowicz, Stanislawa [1 ]
Gray, Stacy W. [2 ]
Wong, Kwok-Kin [2 ]
Chirieac, Lucian R. [1 ]
Lindeman, Neal I. [1 ]
Hornick, Jason L. [1 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Thorac Oncol, Boston, MA 02115 USA
关键词
Anaplastic lymphoma kinase; Lung adenocarcinoma; Fluorescence in situ hybridization; Immunohistochemistry; CANCER; FUSION; MUTATIONS; GEFITINIB; EGFR;
D O I
10.1097/JTO.0b013e31827db604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: ALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leading to anaplastic lymphoma kinase (ALK) overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the standard procedure for detection of ALK rearrangements in lung ACA but requires specialized equipment and expertise. Immunohistochemistry (IHC) for ALK protein overexpression is a promising screening modality, with reports of newer antibodies showing excellent sensitivity and specificity for ALK-rearranged lung ACA. Methods: In this study, we analyzed ALK IHC (5A4 clone) in 186 cases from our clinical service and compared it with ALK FISH and EGFR and KRAS mutation status. Results: Twelve cases had concordant ALK protein overexpression and ALK rearrangement by FISH. Three ALK-rearranged cases lacked ALK protein expression. Of these discrepant cases, one had a coexisting EGFR mutation and a subtle atypical ALK rearrangement manifested as a break in the 5' centromeric portion of the FISH probe. One case had a concurrent BRAF mutation. Follow-up testing on a metastasis revealed absence of the ALK rearrangement, with persistent BRAF mutation. In one ALK-rearranged protein negative case, very limited tissue remained for ALK IHC, raising the possibility of false negativity because of protein expression heterogeneity. Importantly, ALK protein expression was detected in one case initially thought not to have an ALK rearrangement. In this case, FISH was falsely negative because of interference by benign reactive nuclei. After correcting for these cases, ALK IHC was 93% sensitive and 100% specific as compared with FISH. Conclusions: ALK IHC improves the detection of ALK rearrangements when used together with FISH, and its use in lung ACA genetic testing algorithms should be considered.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 50 条
  • [41] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13) : 1189 - 1197
  • [42] ALK-rearranged Tumors Are Highly Enriched in the STUMP Subcategory of Uterine Tumors
    Devereaux, Kelly A.
    Kunder, Christian A.
    Longacre, Teri A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (01) : 64 - 74
  • [43] EXCEPTIONALLY LONG SURVIVAL WITH LORLATINIB IN A PATIENT WITH ALK-REARRANGED LUNG CANCER
    Szklener, Katarzyna
    Nieoczym, Karolina
    Niedziela, Katarzyna
    Swiatlowski, Lukasz
    Mandziuk, Slawomir
    PHARMACOPHORE, 2023, 14 (04): : 1 - 5
  • [44] Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
    Huang, Jie
    Zhang, Shi-Ling
    Zhou, Chaozheng
    Huang, Weiye
    Luo, Peng
    Chen, Hua-Jun
    Yang, Jin-Ji
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
  • [45] Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
    Kim, Soyeon
    Kim, Tae Min
    Kim, Dong-Wan
    Go, Heounjeong
    Keam, Bhumsuk
    Lee, Se-Hoon
    Ku, Ja-Lok
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : 415 - 422
  • [46] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
    Butrynski, James E.
    D'Adamo, David R.
    Hornick, Jason L.
    Dal Cin, Paola
    Antonescu, Cristina R.
    Jhanwar, Suresh C.
    Ladanyi, Marc
    Capelletti, Marzia
    Rodig, Scott J.
    Ramaiya, Nikhil
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Wilner, Keith D.
    Christensen, James G.
    Jaenne, Pasi A.
    Maki, Robert G.
    Demetri, George D.
    Shapiro, Geoffrey I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1727 - 1733
  • [47] Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Mendoza, Dexter P.
    Lin, Jessica J.
    Rooney, Marguerite M.
    Chen, Tianqi
    Sequist, Lecia V.
    Shaw, Alice T.
    Digumarthy, Subba R.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 214 (04) : 766 - 774
  • [48] Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review
    Sasano, Hajime
    Sekine, Akimasa
    Hirata, Toru
    Iwamoto, Keisuke
    Itou, Yuhei
    Itani, Hidetoshi
    Kondou, Shigeto
    Tokui, Toshiya
    Tanigawa, Motoaki
    INTERNAL MEDICINE, 2018, 57 (22) : 3271 - 3275
  • [49] Near complete response to ceritinib in a pediatric patient with metastatic ALK-rearranged lung adenocarcinoma
    Liu, Zuhui
    Liu, Maolin
    Hou, Xue
    LUNG CANCER, 2023, 176 : 140 - 143
  • [50] PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer
    Talwelkar, Sarang S.
    Mayranpaa, Mikko I.
    Schuler, Julia
    Linnavirta, Nora
    Hemmes, Annabrita
    Adinolfi, Simone
    Kankainen, Matti
    Sommergruber, Wolfgang
    Levonen, Anna-Liisa
    Rasanen, Jari
    Knuuttila, Aija
    Verschuren, Emmy W.
    Wennerberg, Krister
    MOLECULAR ONCOLOGY, 2023, 17 (05) : 747 - 764